GSK’s depemokimab shows strong potential for United States Food and Drug Administration approval in asthma and chronic ...

Faulty versions of the LMNA gene can cause a wide range of health problems, including heart muscle disease (dilated ...

Bristol Myers Squibb (BMS) today announced the launch of Kopozgo® (Mavacamten) in India -- the first and only oral, selective cardiac myosin inhibitor approved in the country for the treatment of ...

In a phase 2b trial, danicamtiv, a novel cardiac myosin activator, was well tolerated and associated with improved heart ...

Dying from a broken heart may sound dramatic—but it’s very much a real thing. If you’ve ever experienced a heartbreak so ...

The UB faculty member, mong the top researchers in pediatric cardiomyopathy, is credited with establishing the pediatric ...

Learn about the complications of hypertrophic cardiomyopathy (HCM), including arrhythmias, heart block, and heart failure, as ...

The hereditary transthyretin amyloidosis market is experiencing significant growth driven by increasing disease awareness, ...

Vehicles of all sorts lined a parking lot in Kansas City’s Northland Saturday to honor Tucker Langford, 3, who may have just ...

Beta-blockers have been the cornerstone of treatment for obstructive hypertrophic cardiomyopathy for almost 6 years. Recent ...

The study involved 207 subjects across sites in Canada and the US, who underwent VT ablation using the company’s ULTC system.

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J., October 14, 2025--Kardigan, a heart health company modernizing cardiovascular drug development, announced today the closing of a $254 million Series B ...